



Issuance of a cornerstone patent covering the expression of antibody mixtures

Utrecht, The Netherlands, October 5, 2007- Merus B.V. announced the issuance of an important patent by the United States Patent and Trademark Office. The patent covers the expression of at least three antibodies with different specificities in a single recombinant host cell. It has been demonstrated in several diseases and disease models that mixtures of antibodies are more efficacious than therapies based on single monoclonal antibodies. The claim to express a mixture of antibodies, so called Oligoclronics™, is believed to have important therapeutic value.

In 2004, Merus obtained the exclusive intellectual property rights to the issued patent in return for undisclosed terms and conditions. In June 2004, Merus was granted a research license to use the PER.C6™ cell line for the development of Oligoclronics™. Merus has filed several additional patent applications to further secure its position in this important development of the antibody therapeutics field.

About Merus

Merus is a Dutch Biotechnology company founded in June 2003. The Company is focused on the discovery and development of a novel class of human antibodies, Oligoclronics™, which are expected to have improved efficacy compared to current generations of human monoclonal antibodies. For more information, please visit www.merus.nl.

For further information please contact:

Ton Logtenberg, Ph.D.
CEO Merus B.V.
Tel. +31-(0)-627064066
t.logtenberg@merus.nl
www.merus.nl